Austrade support for PromarkerD, page-26

Hi all, I have not posted on the PIQ board as I only took a small parcel back in December after the collaboration with Janssen was announced.

However yesterday I have topped up significantly and the reason is the study results are impressive (we kinda knew it because study was stopped early, but i like to see results).

It is true that PIQ is not mentioned anywhere in the above article. This is not surprising because PIQ is still analysing the data from this study (see annoucement end of Jan, this will take till approximately June).

However the success of this study is extremely significant for PIQ.

One of the key sentences in the above article is :

"The landmark study evaluated the efficacy and safety of INVOKANA® versus placebo in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) when used in addition to standard of care."

The key points here are that the study has been performed on patients that already suffer from CKD and T2D and that they drug is used in combination with standard of care.

This pretty much means that Janssen, one of the biggest pharma companies worldwide, will have a vast interest in identifying patients that are going to develop CKD in order to sell their drug as early as possible or even as a prophylactic combination therapy, massively increasing their target population. Of course, if the drug can actually work as a prophylactic drug has to be proved, possibly through post hoc analysis that is currently be conducted.

This means that Janssen itself will start to promote the use of promarkerD as a standard of care for T2D disease monitoring, something we already know works and is FDA approved.

Additionally and this is depending on the predictive capabilities that are currently tested, implement promarkerD as a Complementary Diagnostic (CDx) test for patient treated with this new groundbreaking drug.

This pretty much means that the success of this trial has significant implications for PIQ because one of the largest pharma companies worldwide will promote the test in order to increase their own sales, ultimately facilitating marked uptake of promarkerD.

The recent SP weakness hurt my small holding but was/is an amazing opportunity to top up because the success of this trial ensures that Janssen will be very interested in the success of PIQ.